Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Real-world characteristics, treatment patterns, and outcomes of patients with mantle cell lymphoma (MCL) after receiving covalent bruton tyrosine kinase inhibitors (cBTKi) in China

Ningjing Lin, Yuqin Song, Xue Zhang et al. Nov 03, 2025 pp. 2704-2704 10.1182/blood-2025-2704

Abstract Introduction: MCL is an uncommon, aggressive subtype of B-cell non-Hodgkin lymphoma, associated with poor outcomes and limited resp...

Tissue factor bearing microparticles drive thromboinflammation and predict DIC and mortality in sepsis: Results from the roadmap-sepsis study

Patrick Van Dreden, Matthieu grusse, Eleftheria Lefkou et al. Nov 03, 2025 pp. 1302-1302 10.1182/blood-2025-1302

Abstract Background: Thromboinflammation is recognized as a central pathological process in sepsis. Sepsis-induced inflammation, triggered b...

Comparative analysis of efficacy and safety between high-dose TMLI and TBI combined with myeloablative chemotherapy in allogeneic hematopoietic stem cell transplantation for acute leukemia with extramedullary lesions

Zilong Yang, Xinhong Fei, Rongmu Luo et al. Nov 03, 2025 pp. 2417-2417 10.1182/blood-2025-2417

Abstract Background and Significance Total Body Irradiation (TBI) is a key component of conditioning regimens for allogeneic hematopoietic s...

Vitamin K3 metabolic fate determines pro-survival or ferroptotic outcomes in multiple myeloma via UBIAD1 and reductase axis

Yonggang Zhang, Linxiu Mao, Xiaoyu Ran et al. Nov 03, 2025 pp. 1534-1534 10.1182/blood-2025-1534

Abstract While vitamin K1/K2 exert antioxidant effects that protect cancer cells from oxidative stress, The paradoxical role of vitamin K3 (...

Pharmacological mechanism of action and therapeutic potential of a quantitative and qualitative RBC- and hemoglobin-elevating agent AND017 in the Townes SCD model

Jie Bai, Tian Li, Mingzhe Pan et al. Nov 03, 2025 pp. 1154-1154 10.1182/blood-2025-1154

Abstract Sickle cell disease (SCD) is a life-threatening inherited hemoglobinopathy caused by a point mutation in the β-globin gene that res...

Phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed Acute Myeloid Leukemia (AML)

Onyee Chan, Kendra Sweet, Chetasi Talati et al. Nov 03, 2025 pp. 5216-5216 10.1182/blood-2025-5216

Abstract Introduction: About 50-60% of patients (pts) with AML achieve an initial response to intensive chemotherapy but relapses are common...

PTPN11 copy number gain drives leukemogenesis via mutant SHP2 in juvenile myelomonocytic leukemia

Zhiguang Chang, Zhiyong Peng, Lingling Ma et al. Nov 03, 2025 pp. 3234-3234 10.1182/blood-2025-3234

Abstract Juvenile myelomonocytic leukemia (JMML) is a rare but aggressive pediatric myeloproliferative neoplasm driven by hyperactivation of...

Real-world outcomes with eliglustat for gaucher disease type 1 in China: A multicenter retrospective study

Yongxin Zhou, Zijian Hao, Zhuang Qilin et al. Nov 03, 2025 pp. 7980-7980 10.1182/blood-2025-7980

Abstract Background: Gaucher disease type 1 (GD1) is a rare lysosomal storage disorder caused by glucocerebrosidase deficiency, leading to s...

Post allo-HCT menin-inhibition enhances graft-versus-leukemia effects by endogenous retrovirus induction in AML and T-cell activation

Viktor Fetsch, Lennard Schwöbel, Ezgi Göknar et al. Nov 03, 2025 pp. 5862-5862 10.1182/blood-2025-5862

Abstract Acute myeloid leukemia (AML) with chromosomal rearrangements involving the lysine methyltransferase 2A (KMT2A) gene and mutations i...

Hallmarks of allogeneic hematopoietic cell transplant success: A study on immune signatures and predictive features of graft versus host disease-free remission states from the SFGM-TC registry and cryostem biobank

Adrien Lapoutge, Mélanie Gaudfrin, Nicole Raus et al. Nov 03, 2025 pp. 2476-2476 10.1182/blood-2025-2476

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) remains the cornerstone of curative therapy for patients with myelodysplas...

Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia (AML), associated with decreased inflammatory response patterns, and favorable outcomes in young male patients (pts)

Maria Velegraki, Cankun Wang, Deedra Nicolet et al. Nov 03, 2025 pp. 1723-1723 10.1182/blood-2025-1723

Abstract Loss of the Y chromosome (LOY) is often detected in AML, yet it has been mostly considered inconsequential, assuming it is associat...

Labile heparin response in a pre-operative cardiac surgery patient: Unmasking predisposition for post-operative coagulopathy

Kayleigh Edwards, Rahul Deshmukh, Leo Reap Nov 03, 2025 pp. 6632-6632 10.1182/blood-2025-6632

Abstract Candidacy for coronary artery bypass grafting (CABG) is generally dependent on the extent of atherosclerotic burden within coronary...

Clinical experience with efanesoctocog alfa in patients with uncover needs on emicizumab

Julia COLL Vallier, CRISTINA SIERRA AISA, Edwin Suarez Merchan et al. Nov 03, 2025 pp. 6624-6624 10.1182/blood-2025-6624

Abstract Introduction Despite therapeutic advances, hemophilia A (HA) remains associated with joint bleeding, severe hemophilic arthropathy...

In Vivo evaluation of autologous serum eye drops obtained via a closed-circuit collection device: Preliminary analysis of a Phase 2 pilot trial

Giancarlo Fatobene, Luciana Olivalves, Caio Almeida et al. Nov 03, 2025 pp. 4247-4247 10.1182/blood-2025-4247

Abstract Introduction: Autologous serum eye drops (ASED) are an established therapy for ocular surface diseases, with reported average sympt...

Multistep molecular trajectory during monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells

Yu Inoue, Yuji Shimura, Yui Niiyama-Uchibori et al. Nov 03, 2025 pp. 7091-7091 10.1182/blood-2025-7091

Abstract The treatment landscape of diffuse large B-cell lymphoma (DLBCL) has progressed with the emergence of immune-cell therapies (ICTs),...

DOT1L/menin inhibitors target replication fork plasticity and create novel vulnerability to PARP inhibitor in MLL-rearranged AML

Tsz Kan Fung, Cyril Dördelmann, Danyue Peng et al. Nov 03, 2025 pp. 867-867 10.1182/blood-2025-867

Abstract Epigenetic deregulation is a major driver for acute myeloid leukemia (AML) including those with Mixed-Lineage Leukemia gene-rearran...

Haploidentical and neonatal combined transplant generates GVL effect in a murine model of haplo-cord transplant.

Eric Irons, Alex Huang, Koen van Besien Nov 03, 2025 pp. 4092-4092 10.1182/blood-2025-4092

Abstract Favorable outcomes after hematopoietic stem cell transplant depend on the availability of HLA-matched donors, which varies signific...

Dissecting the heterogeneity of IGHV-mutated CLL: An eric study.

Thomas Chatzikonstantinou, Andreas Agathangelidis, Persefoni Talimtzi et al. Nov 03, 2025 pp. 2120-2120 10.1182/blood-2025-2120

Abstract Introduction: Patients with CLL and mutated immunoglobulin heavy variable (IGHV) genes (M-CLL) are clinically heterogeneous. While...

Interleukin-27 ameliorates inflammation-induced chronic pain in sickle cell disease

Adekunle Alagbe, Lynda Little-Ihrig, Michael Gold et al. Nov 03, 2025 pp. 4709-4709 10.1182/blood-2025-4709

Abstract Sickle cell disease (SCD) causes debilitating chronic pain in over 50% of adults, highlighting the urgent need for new non-opioid-b...

AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning

Andre De Menezes Silva Corraes, Emmanuel Contreras Guzman, Monica Shaw et al. Nov 03, 2025 pp. 6131-6131 10.1182/blood-2025-6131

Abstract Introduction: CAR-T therapy has transformed cancer therapy. with its first Food and Drug Administration (FDA) approved product in A...

Comprehensive analysis of long-term outcomes in adult patients with acute lymphoblastic leukemia who received allogeneic stem cell transplantation: Real-world data of the Korean society of blood and marrow transplantation registry

Dong Won Baek, Je-Hwan Lee, Joon Seong Park et al. Nov 03, 2025 pp. 4286-4286 10.1182/blood-2025-4286

Abstract Background/Aims Allogeneic stem cell transplantation (allo-SCT) is a curative option in adult patients with acute lymphoblastic leu...

Incidence of heart failure in patients with acute myeloid leukemia who received daunorubicin versus idarubicin: An analysis of the trinetx database

Ayush Kaushish, Quan Do Nov 03, 2025 pp. 873-873 10.1182/blood-2025-873

Abstract Background The 7+3 regimen, which combines 7 days of cytarabine with 3 days of an anthracycline, continues to be a cornerstone of i...

A national lens on follicular lymphoma: Academic care linked to improved survival in 158,000 patients

Daniel Rosas, Leyla Bojanini, Supreet Kaur et al. Nov 03, 2025 pp. 2628-2628 10.1182/blood-2025-2628

Abstract Background Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma in the United States and Eur...

Daratumumab, bortezomib, lenalidomide and dexamethasone, upfront autologous transplant and lenalidomide maintenance for newly diagnosed multiple myeloma

Oren Pasvolsky, Muhammad Bilal Abid, Denai Milton et al. Nov 03, 2025 pp. 7509-7509 10.1182/blood-2025-7509

Abstract Background: The quadruplet induction regimen of daratumumab, bortezomib, lenalidomide (Len), and dexamethasone (DVRD) has shown dee...

Longer survival with tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a real-world analysis

Anthony Selwyn Stein, Guru Subramanian Guru Murthy, Pankit Vachhani et al. Nov 03, 2025 pp. 4612-4612 10.1182/blood-2025-4612

Abstract Background BPDCN is an orphan and aggressive hematologic malignancy characterized by CD123 expression and frequent involvement of t...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page